메뉴 건너뛰기




Volumn 28, Issue 8, 2011, Pages

Endothelin receptor antagonists-their role in pulmonary medicine

Author keywords

Ambrisentan; Bosentan; Endothelin receptor antagonists; Pulmonary arterial hypertension; Pulmonary fibrosis; Sitaxentan

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN 1; PLACEBO; SITAXSENTAN;

EID: 84155162559     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2009.07.001     Document Type: Review
Times cited : (9)

References (101)
  • 2
    • 4644290657 scopus 로고    scopus 로고
    • Treatment of pulmonary arterial hypertension
    • Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
    • (2004) N Engl J Med , vol.351 , pp. 1425-36
    • Humbert, M.1    Sitbon, O.2    Simonneau, G.3
  • 3
    • 40649084619 scopus 로고    scopus 로고
    • Endothelin receptor antagonists in pulmonary hypertension
    • Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary hypertension. Eur Respir J 2008;31:407-15.
    • (2008) Eur Respir J , vol.31 , pp. 407-415
    • Dupuis, J.1    Hoeper, M.M.2
  • 4
    • 70049091002 scopus 로고    scopus 로고
    • Endothelin receptor antagonists for pulmonary arterial hypertension
    • Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2009;3:CD004434.
    • (2009) Cochrane Database Syst Rev , vol.3
    • Liu, C.1    Chen, J.2
  • 5
    • 10044258461 scopus 로고    scopus 로고
    • Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology
    • Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
    • (2004) Eur Heart J , vol.25 , pp. 2243-78
    • Galiè, N.1    Torbicki, A.2    Barst, R.3
  • 7
    • 33645720494 scopus 로고    scopus 로고
    • Signalisation cellulaire et physiopathologie de l'hypertension artérielle pulmonaire
    • Dao P, Montani D, Duong-Quy S, et al. Signalisation cellulaire et physiopathologie de l'hypertension artérielle pulmonaire. Rev Mal Respir 2006;23:3S75-83S.
    • (2006) Rev Mal Respir , vol.23
    • Dao, P.1    Montani, D.2    Duong-Quy, S.3
  • 8
    • 0028793495 scopus 로고
    • Endothelin-1 as an autocrine growth factor for endothelial cells
    • Eguchi S, Hirata Y, Imai T, et al. Endothelin-1 as an autocrine growth factor for endothelial cells. J Cardiovasc Pharmacol 1995;26:S279-83.
    • (1995) J Cardiovasc Pharmacol , vol.26
    • Eguchi, S.1    Hirata, Y.2    Imai, T.3
  • 9
    • 0026034713 scopus 로고
    • Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
    • Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9.
    • (1991) Ann Intern Med , vol.114 , pp. 464-469
    • Stewart, D.J.1    Levy, R.D.2    Cernacek, P.3
  • 10
    • 0035818267 scopus 로고    scopus 로고
    • Endothelin receptor antagonists in pulmonary hypertension
    • Dupuis J. Endothelin receptor antagonists in pulmonary hypertension. Lancet 2001;358:1113.
    • (2001) Lancet , vol.358 , pp. 1113
    • Dupuis, J.1
  • 14
    • 0029741347 scopus 로고    scopus 로고
    • Human pulmonary circulation is an important site for both clearance and production of endothelin-1
    • Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary circulation is an important site of both clearance and production of endothelin-1. Circulation 1996;94:1578-84. (Pubitemid 26320261)
    • (1996) Circulation , vol.94 , Issue.7 , pp. 1578-1584
    • Dupuis, J.1    Stewart, D.J.2    Cernacek, P.3    Gosselin, G.4
  • 15
    • 34548151315 scopus 로고    scopus 로고
    • B receptor interactions
    • DOI 10.1159/000102534
    • Sauvageau S, Thorin E, Caron A, et al. Endothelin-1-induced pulmonary vaso reactivity is regulated by ETA and ETB receptor interactions. J Vasc Res 2007;44:375-81. (Pubitemid 47312658)
    • (2007) Journal of Vascular Research , vol.44 , Issue.5 , pp. 375-381
    • Sauvageau, S.1    Thorin, E.2    Caron, A.3    Dupuis, J.4
  • 18
    • 0037022927 scopus 로고    scopus 로고
    • Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension
    • DOI 10.1161/hc0902.105719
    • Bauer M, Wilkens H, Langer F, et al. Selective up-regulation of endothelin b receptor gene expression in severe pulmonary hypertension. Circulation 2002;105:1034-6. (Pubitemid 34212609)
    • (2002) Circulation , vol.105 , Issue.9 , pp. 1034-1036
    • Bauer, M.1    Wilkens, H.2    Langer, F.3    Schneider, S.O.4    Lausberg, H.5    Schafers, H.-J.6
  • 19
    • 41149100981 scopus 로고    scopus 로고
    • Endothéline-1 et sélectivité des antagonistes des récepteurs de l'endothéline 1: to B or not to B?
    • Marie I, Bekri S, Lévesque H. Endothéline-1 et sélectivité des antagonistes des récepteurs de l'endothéline 1: to B or not to B? Rev Med Interne 2008:263-8.
    • (2008) Rev Med Interne , pp. 263-268
    • Marie, I.1    Bekri, S.2    Lévesque, H.3
  • 20
    • 49749102732 scopus 로고    scopus 로고
    • Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: Does selectivity matter?
    • Opitz CF, Ewert R, Kirch W, et al. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J 2008;29: 1936-48.
    • (2008) Eur Heart J , vol.29 , pp. 1936-48
    • Opitz, C.F.1    Ewert, R.2    Kirch, W.3
  • 21
    • 25844464249 scopus 로고    scopus 로고
    • Hypertension artérielle pulmonaire
    • Montani D, Jais X, Sitbon O, et al. Hypertension artérielle pulmonaire. Rev Mal Respi 2005;22:651-66.
    • (2005) Rev Mal Respi , vol.22 , pp. 651-666
    • Montani, D.1    Jais, X.2    Sitbon, O.3
  • 22
    • 70349634397 scopus 로고    scopus 로고
    • Guidelines for the disgnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the international Society of Heartband Lung Transplantation (ISHLT)
    • Galié N, Hoeper MM, Humbert M, et al. Guidelines for the disgnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the international Society of Heartband Lung Transplantation (ISHLT). Eur Respir J 2009;34:1219-63.
    • (2009) Eur Respir J , vol.34 , pp. 1219-63
    • Galié, N.1    Hoeper, M.M.2    Humbert, M.3
  • 23
    • 0030031888 scopus 로고    scopus 로고
    • A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension
    • Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302.
    • (1996) N Engl J Med , vol.334 , pp. 296-302
    • Barst, R.J.1    Rubin, L.J.2    Long, W.A.3
  • 26
    • 0035986906 scopus 로고    scopus 로고
    • Bosentan: A dual endothelin receptor antagonist
    • DOI 10.1517/13543784.11.7.991
    • Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Investig Drugs 2002;11:991-1002. (Pubitemid 34732717)
    • (2002) Expert Opinion on Investigational Drugs , vol.11 , Issue.7 , pp. 991-1002
    • Rubin, L.J.1    Roux, S.2
  • 27
    • 0037214229 scopus 로고    scopus 로고
    • Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist
    • DOI 10.1177/0091270002239701
    • Van Giersbergen PLM, Popescu G, Bodin F, et al. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol 2003;43:15-22. (Pubitemid 36015438)
    • (2003) Journal of Clinical Pharmacology , vol.43 , Issue.1 , pp. 15-22
    • Van Giersbergen, P.L.M.1    Popescu, G.2    Bodin, F.3    Dingemanse, J.4
  • 28
    • 0035991888 scopus 로고    scopus 로고
    • Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist
    • Dingemanse J, Van Giersbergen PLM. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int J Clin Pharmacol Ther 2002;40:310-6. (Pubitemid 34732808)
    • (2002) International Journal of Clinical Pharmacology and Therapeutics , vol.40 , Issue.7 , pp. 310-316
    • Dingemanse, J.1    Van Giersbergen, P.L.M.2
  • 29
    • 0033338133 scopus 로고    scopus 로고
    • Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin
    • Weber C, Banken L, Birnboeck H, et al. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarine. J Clin Pharmacol 1999;39:847-54. (Pubitemid 30629445)
    • (1999) Journal of Clinical Pharmacology , vol.39 , Issue.8 , pp. 847-854
    • Weber, C.1    Banken, L.2    Birnboeck, H.3    Schulz, R.4
  • 36
    • 33746206340 scopus 로고    scopus 로고
    • Bosentan therapy in patients with Eisenmenger syndrome: A multicenter, double-blind, randomized, placebo-controlled study
    • DOI 10.1161/CIRCULATIONAHA.106.630715, PII 0000301720060704000012
    • Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome. A multicenter, double-blind randomised, placebo-controlled study. Circulation 2006;114:48-54. (Pubitemid 44305274)
    • (2006) Circulation , vol.114 , Issue.1 , pp. 48-54
    • Galie, N.1    Beghetti, M.2    Gatzoulis, M.A.3    Granton, J.4    Berger, R.M.F.5    Lauer, A.6    Chiossi, E.7    Landzberg, M.8
  • 37
    • 45249119855 scopus 로고    scopus 로고
    • Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): A double-blind, randomised controlled trial
    • DOI 10.1016/S0140-6736(08)60919-8, PII S0140673608609198
    • Galiè N, Rubin LJ, Hoeper MM, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100. (Pubitemid 351902178)
    • (2008) The Lancet , vol.371 , Issue.9630 , pp. 2093-2100
    • Galie, N.1    Rubin, L.2    Hoeper, M.3    Jansa, P.4    Al-Hiti, H.5    Meyer, G.6    Chiossi, E.7    Kusic-Pajic, A.8    Simonneau, G.9
  • 38
    • 57449103127 scopus 로고    scopus 로고
    • Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (BENEFiT) a randomised placebo-controlled trial
    • Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group
    • Jaïs X, D'Armini AM, Jansa P, et al. Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (BENEFiT) a randomised placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-34.
    • (2008) J Am Coll Cardiol , vol.52 , pp. 2127-34
    • Jaïs, X.1    D'Armini, A.M.2    Jansa, P.3
  • 40
    • 0037484589 scopus 로고    scopus 로고
    • Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension a 1-year follow-up study
    • DOI 10.1378/chest.124.1.247
    • Sitbon O, Badesch DB, Channick R, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension. A 1-year follow-up study. Chest 2003;124:247-54. (Pubitemid 36851359)
    • (2003) Chest , vol.124 , Issue.1 , pp. 247-254
    • Sitbon, O.1    Badesch, D.B.2    Channick, R.N.3    Frost, A.4    Bobbins, I.M.5    Simonneau, G.6    Tapson, V.F.7    Rubin, L.J.8
  • 42
    • 33645243403 scopus 로고    scopus 로고
    • Long-term outcome with first-line bosentan therapy in idiopathic pulmonary hypertension
    • Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary hypertension. Eur Heart J 2006;27:589-95.
    • (2006) Eur Heart J , vol.27 , pp. 589-595
    • Provencher, S.1    Sitbon, O.2    Humbert, M.3
  • 43
    • 27744444638 scopus 로고    scopus 로고
    • Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
    • DOI 10.1136/thx.2005.040618
    • Sitbon O, McLaughlin VV, Badesch DB, et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of patients started on intravenous epoprostnol. Thorax 2005;60:1025-30. (Pubitemid 41705471)
    • (2005) Thorax , vol.60 , Issue.12 , pp. 1025-1030
    • Sitbon, O.1    McLaughlin, V.V.2    Badesch, D.B.3    Barst, R.J.4    Black, C.5    Galie, N.6    Humbert, M.7    Rainisio, M.8    Rubin, L.J.9    Simonneau, G.10
  • 44
    • 34250870730 scopus 로고    scopus 로고
    • Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines
    • DOI 10.1378/chest.06-2674
    • Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice Guidelines. Chest 2007;131: 1917-28. (Pubitemid 46981654)
    • (2007) Chest , vol.131 , Issue.6 , pp. 1917-1928
    • Badesch, D.B.1    Abman, S.H.2    Simonneau, G.3    Rubin, L.J.4    McLaughlin, V.V.5
  • 45
    • 33750344748 scopus 로고    scopus 로고
    • Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions
    • DOI 10.1136/ard.2005.048967
    • Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40. (Pubitemid 44620443)
    • (2006) Annals of the Rheumatic Diseases , vol.65 , Issue.10 , pp. 1336-1340
    • Denton, C.P.1    Humbert, M.2    Rubin, L.3    Black, C.M.4
  • 47
    • 0037331116 scopus 로고    scopus 로고
    • Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis
    • DOI 10.1378/chest.123.2.344
    • Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50. (Pubitemid 36269414)
    • (2003) Chest , vol.123 , Issue.2 , pp. 344-350
    • Kawut, S.M.1    Taichman, D.B.2    Archer-Chicko, C.L.3    Palevsky, H.I.4    Kimmel, S.E.5
  • 48
    • 50249155984 scopus 로고    scopus 로고
    • Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue disease
    • Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue disease. Ann Rheum Dis 2008;67:1222-8.
    • (2008) Ann Rheum Dis , vol.67 , pp. 1222-1228
    • Denton, C.P.1    Pope, J.E.2    Peter, H.H.3
  • 54
    • 70149121675 scopus 로고    scopus 로고
    • Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: Results of the COMPASS-1 study
    • Gruenig E, Michelakis E, Vachiéry JL, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol 2009;49:1343-52.
    • (2009) J Clin Pharmacol , vol.49 , pp. 1343-52
    • Gruenig, E.1    Michelakis, E.2    Vachiéry, J.L.3
  • 56
    • 38049089932 scopus 로고    scopus 로고
    • Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil
    • Burgess G, Hoogkamer H, Collins L, et al. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008;64:43-50.
    • (2008) Eur J Clin Pharmacol , vol.64 , pp. 43-50
    • Burgess, G.1    Hoogkamer, H.2    Collins, L.3
  • 57
    • 44949089427 scopus 로고    scopus 로고
    • Ambrisentan for the management of pulmonary arterial hypertension
    • DOI 10.1016/j.clinthera.2008.05.005, PII S0149291808001756
    • Cheng JWM. Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 2008;30:825-33. (Pubitemid 351802283)
    • (2008) Clinical Therapeutics , vol.30 , Issue.5 , pp. 825-833
    • Cheng, J.W.M.1
  • 58
    • 34249854139 scopus 로고    scopus 로고
    • A review of pulmonary arterial hypertension: Role of ambrisentan
    • Barst RJ. A review of pulmonary hypertension: role of ambrisentan. Vasc Health Risk Mana 2007;3:11-22. (Pubitemid 46860713)
    • (2007) Vascular Health and Risk Management , vol.3 , Issue.1 , pp. 11-22
    • Barst, R.J.1
  • 59
    • 34249852488 scopus 로고    scopus 로고
    • Non clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil
    • Dufton C, Gerber MJ, Yin O. Non clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil. Chest 2006;130:254S.
    • (2006) Chest , vol.130
    • Dufton, C.1    Gerber, M.J.2    Yin, O.3
  • 60
    • 34249855849 scopus 로고    scopus 로고
    • Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin
    • Gerber MJ, Dufton C, Pentikis H. Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin. Chest 2006;130:256S.
    • (2006) Chest , vol.130
    • Gerber, M.J.1    Dufton, C.2    Pentikis, H.3
  • 62
    • 46449124591 scopus 로고    scopus 로고
    • Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomised, double-blind, placebo-controlledm multicenter efficacy (ARIES) study 1 and 2
    • 0-10
    • Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomised, double-blind, placebo-controlledm multicenter efficacy (ARIES) study 1 and 2. Circulation 2008;117: 0-10.
    • (2008) Circulation , vol.117
    • Galiè, N.1    Olschewski, H.2    Oudiz, R.J.3
  • 63
    • 41149113972 scopus 로고    scopus 로고
    • La prise en charge thérapeutique de l'hypertension artérielle pulmonaire par les antagonistes des récepteurs de l'endothéline en 2008
    • Cacoub P, Amoura Z, Langleben D. La prise en charge thérapeutique de l'hypertension artérielle pulmonaire par les antagonistes des récepteurs de l'endothéline en 2008. Rev Med Int 2008;29:283-9.
    • (2008) Rev Med Int , vol.29 , pp. 283-289
    • Cacoub, P.1    Amoura, Z.2    Langleben, D.3
  • 66
    • 0036283401 scopus 로고    scopus 로고
    • Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: Open-label pilot study
    • DOI 10.1378/chest.121.6.1860
    • Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxentan, an oral endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest 2002;121:1860-8. (Pubitemid 34634407)
    • (2002) Chest , vol.121 , Issue.6 , pp. 1860-1868
    • Barst, R.J.1    Rich, S.2    Widlitz, A.3    Horn, E.M.4    McLaughlin, V.5    McFarlin, J.6
  • 67
    • 33646255654 scopus 로고    scopus 로고
    • Treatment of pulmonary arterial hypertension wtih the selective endothelin-receptor antagonist sitaxsentan
    • Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension wtih the selective endothelin-receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56.
    • (2006) J Am Coll Cardiol , vol.47 , pp. 2049-56
    • Barst, R.J.1    Langleben, D.2    Badesch, D.3
  • 68
    • 33645047236 scopus 로고    scopus 로고
    • Warfarin management in pulmonary arterial hypertension is similar between bosentan, placebo, and sitaxentan
    • Coyne T, Dixon R. Warfarin management in pulmonary arterial hypertension is similar between bosentan, placebo, and sitaxentan. Chest 2005;128:366S.
    • (2005) Chest , vol.128
    • Coyne, T.1    Dixon, R.2
  • 71
    • 33847317730 scopus 로고    scopus 로고
    • Chronic treatment of pulmonary arterial hypertension with sitaxentan and bosentan
    • Benza R, Frost A, Girgis R. Chronic treatment of pulmonary arterial hypertension with sitaxentan and bosentan. Proc Am Thorac Soc 2006;3:A729.
    • (2006) Proc Am Thorac Soc , vol.3
    • Benza, R.1    Frost, A.2    Girgis, R.3
  • 75
    • 2942541475 scopus 로고    scopus 로고
    • Cellular and molecular pathobiology of pulmonary arterial hypertension
    • Humbert M, Morel NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13-24.
    • (2004) J Am Coll Cardiol , vol.43 , pp. 13-24
    • Humbert, M.1    Morel, N.W.2    Archer, S.L.3
  • 76
    • 35648934472 scopus 로고    scopus 로고
    • Selective and mixed endothelin receptor antagonism in cardiovascular disease
    • DOI 10.1016/j.tips.2007.10.002, PII S016561470700226X
    • Dhaun N, Pollock DM, Goddard J, et al. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 2007;28:573-9. (Pubitemid 350026612)
    • (2007) Trends in Pharmacological Sciences , vol.28 , Issue.11 , pp. 573-579
    • Dhaun, N.1    Pollock, D.M.2    Goddard, J.3    Webb, D.J.4
  • 77
    • 0025836185 scopus 로고
    • Endothelin, an endothelial-dependant vasoconstrictor in scleroderma. Enhanced production and profibrotic action
    • Kahaleh MB. Endothelin, an endothelial-dependant vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83.
    • (1991) Arthritis Rheum , vol.34 , pp. 978-983
    • Kahaleh, M.B.1
  • 79
    • 0028520783 scopus 로고
    • Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro
    • Cambrey AD, Harrison NK, Dawes KE, et al. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Moll Biol 1994;11:439-45.
    • (1994) Am J Respir Cell Moll Biol , vol.11 , pp. 439-445
    • Cambrey, A.D.1    Harrison, N.K.2    Dawes, K.E.3
  • 81
    • 85008987259 scopus 로고    scopus 로고
    • International multidisciplinary consensus classification of the idiopathic interstitial pneumonias
    • American Thoracic Society/European Respiratory Society
    • American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;65:277-304.
    • (2002) Am J Respir Crit Care Med , vol.65 , pp. 277-304
  • 84
    • 0037137109 scopus 로고    scopus 로고
    • Traitement de la fibrose pulmonaire
    • Cottin V. Traitement de la fibrose pulmonaire. Presse Med 2002;31:1613-23. (Pubitemid 36292106)
    • (2002) Presse Medicale , vol.31 , Issue.34 , pp. 1613-1623
    • Cottin, V.1
  • 85
    • 51549101867 scopus 로고    scopus 로고
    • Interstitial lung disease guideline: The British Thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society
    • British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of care Committee; Thoracic Society of Australia, New Zealand Thoracic Society; Irish Thoracic Society
    • Wells AU, Hirani N, British Thoracic Society, Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of care Committee; Thoracic Society of Australia, New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63:v1-58.
    • (2008) Thorax , vol.63
    • Wells, A.U.1    Hirani, N.2
  • 88
    • 77749324295 scopus 로고    scopus 로고
    • Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebocontrolled trial results
    • Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebocontrolled trial results. Am J Respir Crit Care Med 2010;181:604-10.
    • (2010) Am J Respir Crit Care Med , vol.181 , pp. 604-610
    • Daniels, C.E.1    Lasky, J.A.2    Limper, A.H.3
  • 90
    • 0035895243 scopus 로고    scopus 로고
    • Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy
    • Selman M, King Jr TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134: 136-51. (Pubitemid 32096342)
    • (2001) Annals of Internal Medicine , vol.134 , Issue.2 , pp. 136-151
    • Selman, M.1    King Jr., T.E.2    Pardo, A.3
  • 91
    • 25444457220 scopus 로고    scopus 로고
    • Idiopathic pulmonary fibrosis: An epithelial: Fibroblastic cross-talk disorder
    • Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial: fibroblastic cross-talk disorder. Respir Res 2002;3:3-10.
    • (2002) Respir Res , vol.3 , pp. 3-10
    • Selman, M.1    Pardo, A.2
  • 93
    • 36348938856 scopus 로고    scopus 로고
    • Bosentan et fibrose pulmonaire
    • DOI 10.1016/S0248-8663(07)80022-1, PII S0248866307800221
    • Cottin V, Cordier JF. Bosentan et fibrose pulmonaire. Rev Med Intern 2007;28:S230-7. (Pubitemid 350148234)
    • (2007) Revue de Medecine Interne , vol.28 , Issue.SUPPL. 3
    • Cottin, V.1    Cordier, J.-F.2
  • 97
    • 37849012578 scopus 로고    scopus 로고
    • BUILD-1: A randomised placebo-controlled trial of Bosentan in idiopathic pulmonary fibrosis
    • King Jr TE, Behr J, Brown KK, et al. BUILD-1: a randomised placebo-controlled trial of Bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008;177:75-81.
    • (2008) Am J Respir Crit Care Med , vol.177 , pp. 75-81
    • King Jr., T.E.1    Behr, J.2    Brown, K.K.3
  • 98
    • 54949126557 scopus 로고    scopus 로고
    • High-resolution computed tomography (HRCT) features correlate with response to bosentan in idiopathic pulmonary fibrosis (IPF): The BUILD-1study
    • Lynch DA, Behr J, Brown KK, et al. High-resolution computed tomography (HRCT) features correlate with response to bosentan in idiopathic pulmonary fibrosis (IPF): the BUILD-1study. Am Thorac Soc Int Conf 2007:A567.
    • (2007) Am Thorac Soc Int Conf
    • Lynch, D.A.1    Behr, J.2    Brown, K.K.3
  • 99
    • 80051566676 scopus 로고    scopus 로고
    • BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis
    • King Jr TE, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:92-9.
    • (2011) Am J Respir Crit Care Med , vol.184 , pp. 92-99
    • King Jr., T.E.1    Brown, K.K.2    Raghu, G.3
  • 100
    • 33845287938 scopus 로고    scopus 로고
    • Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis (SSc): The BUILD-2 study
    • Seibold JR, Black CM, Denton CP, et al. Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis (SSc): the BUILD-2 study. Proc Am Thorac 2006;3:A243.
    • (2006) Proc Am Thorac , vol.3
    • Seibold, J.R.1    Black, C.M.2    Denton, C.P.3
  • 101
    • 33744922911 scopus 로고    scopus 로고
    • Profile of past and current clinical trials involving endothelin receptor antagonists: The novel '-sentan' class of drug
    • Battistini B, Berthaume N, Kelland NF, et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the Novel "-Sentan" class of drug. Exp Biol Med 2006;231:653-95. (Pubitemid 43845510)
    • (2006) Experimental Biology and Medicine , vol.231 , Issue.6 , pp. 653-695
    • Battistini, B.1    Berthiaume, N.2    Kelland, N.F.3    Webb, D.J.4    Kohan, D.E.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.